Abstract
Blood pressure (BP) changes during alemtuzumab infusions are poorly understood. The aim of this study was to examine BP changes during alemtuzumab infusions in persons with multiple sclerosis (PwMS). This was a retrospective cohort review of systolic (S) and diastolic (D) BP in PwMS receiving alemtuzumab. Thirty-one patients were identified; 22 (64.5%) were women. Mean age and disease duration were 35.2±7.1 and 9.2±5.4years, respectively. There was no history of hypertension or vascular events. Mean baseline SBP was 119.8±15.1mmHg, 118.8±14.3mmHg and 106.5±6.1mmHg whilst mean DBP was 75.3±9.2mmHg, 74.1±12.4mmHg and 69.2±4.3mmHg at doses 1, 6 and 9, respectively. During the first cycle, SBP increased by 19.2±9.4mmHg, with comparable percentage increases over the five infusions (16%, 22%, 17%, 11%, 13%, respectively). DBP increased by 6.2±3.8mmHg with similar percentage increases over the five infusions (8.4%, 11.5%, 5.5%, 7%, 3%). For the second cycle, SBP increased by 16.9±3.2mmHg, with similar increases over the 3days (12%, 15%, 17%). DBP increased by 5.4±4.2mmHg (11%, 9%, 12.8%). The third cycle demonstrated increased mean and percentage of SBP and DBP by 8.9±2.3mmHg (10%, 70%, 11.8%) and 4.2±1.9mmHg (3%, 2%, 6.5%), respectively. Collectively, for 31 patients, in the first cycle, mean SBP increased from 119.8±15.1mmHg to 138.8±13mmHg (p˂0.001), whilst mean DBP increased from 74.5±9.2mmHg to 79.2±9.1mmHg (p=0.007). Overall, 17 (54.8%) patients had increasing BP by ≥20% and nine (29%) had increasing BP by ≥20mmHg from baseline. This demonstrates significant increases in BP during alemtuzumab infusions in PwMS.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.